Trial Profile
Phase 2 Study of OT-551 Ophthalmic Solution to Prevent or Delay Progression of Nuclear Cataract Formation In Post-Vitrectomy Patients
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 May 2014
Price :
$35
*
At a glance
- Drugs CPC 551 (Primary)
- Indications Cataracts
- Focus Therapeutic Use
- Sponsors Othera Pharmaceuticals
- 23 May 2014 New trial record